Legacy Bridge LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 6,027.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,983 shares of the company’s stock after acquiring an additional 3,918 shares during the quarter. Eli Lilly and comprises approximately 1.0% of Legacy Bridge LLC’s portfolio, making the stock its 25th biggest holding. Legacy Bridge LLC’s holdings in Eli Lilly and were worth $1,457,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Benjamin Edwards Inc. increased its position in shares of Eli Lilly and by 0.7% during the third quarter. Benjamin Edwards Inc. now owns 3,836 shares of the company’s stock valued at $1,240,000 after acquiring an additional 28 shares in the last quarter. Moloney Securities Asset Management LLC boosted its holdings in Eli Lilly and by 0.6% in the third quarter. Moloney Securities Asset Management LLC now owns 5,000 shares of the company’s stock worth $1,617,000 after purchasing an additional 28 shares during the last quarter. Auxano Advisors LLC boosted its holdings in Eli Lilly and by 2.1% in the third quarter. Auxano Advisors LLC now owns 1,385 shares of the company’s stock worth $448,000 after purchasing an additional 28 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in Eli Lilly and by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 1,774 shares of the company’s stock worth $574,000 after purchasing an additional 29 shares during the last quarter. Finally, Platform Technology Partners boosted its holdings in Eli Lilly and by 1.6% in the fourth quarter. Platform Technology Partners now owns 1,860 shares of the company’s stock worth $681,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 82.13% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. Guggenheim raised their target price on shares of Eli Lilly and from $399.00 to $401.00 and gave the stock a “buy” rating in a report on Wednesday, December 7th. Cowen lifted their target price on shares of Eli Lilly and from $390.00 to $430.00 in a research note on Monday, December 5th. UBS Group lowered their target price on shares of Eli Lilly and from $428.00 to $420.00 and set a “buy” rating on the stock in a research note on Thursday, December 15th. Jefferies Financial Group started coverage on shares of Eli Lilly and in a research note on Monday, March 6th. They set a “hold” rating and a $290.00 target price on the stock. Finally, Wells Fargo & Company upgraded shares of Eli Lilly and from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $360.00 to $375.00 in a research note on Monday, March 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and has a consensus rating of “Moderate Buy” and a consensus target price of $382.05.
Eli Lilly and Stock Performance
Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings results on Thursday, February 2nd. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $1.83 by $0.26. The company had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.39 billion. Eli Lilly and had a net margin of 21.88% and a return on equity of 73.61%. The firm’s revenue was down 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.49 EPS. Research analysts predict that Eli Lilly and Company will post 8.49 EPS for the current year.
Insider Activity at Eli Lilly and
In related news, EVP Anne E. White sold 2,500 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $342.76, for a total transaction of $856,900.00. Following the transaction, the executive vice president now directly owns 60,426 shares in the company, valued at approximately $20,711,615.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.12% of the stock is currently owned by insiders.
Eli Lilly and Profile
Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Get Rating).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.